Mabion S.A. Market Cap ($35.14 Million)
Market Cap & Net Worth: Mabion S.A. (MAB)
Mabion S.A. market cap. Mabion S.A. (WAR:MAB) has a market capitalization of $35.14 Million (zł127.68 Million) as of November 1, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #23015 globally and #220 in its home market, demonstrating a -5.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mabion S.A.'s stock price zł7.90 by its total outstanding shares 16162326 (16.16 Million). Also see Mabion S.A. cash conversion from operations for how efficiently the company converts equity into cash flow.
Mabion S.A. Market Cap History (2015–2026)
Mabion S.A. market cap history from 2015 to 2026. Data shows change from $208.88 Million to $35.14 Million (-15.21% CAGR). Check MAB live share price for real-time trading data and today's change.
Mabion S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mabion S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MAB net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.97x
Mabion S.A.'s market cap is 1.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $92.30 Million | $1.59 Million | -$57.19 Million | 58.05x | N/A |
| 2021 | $271.78 Million | $56.87 Million | $1.90 Million | 4.78x | 142.82x |
| 2022 | $93.41 Million | $163.98 Million | $23.19 Million | 0.57x | 4.03x |
| 2023 | $80.73 Million | $151.68 Million | $41.27 Million | 0.53x | 1.96x |
| 2024 | $39.59 Million | $69.02 Million | -$6.33 Million | 0.57x | N/A |
| 2025 | $31.05 Million | $15.76 Million | -$62.61 Million | 1.97x | N/A |
Competitor Companies of MAB by Market Capitalization
Companies near Mabion S.A. in the global market cap rankings as of November 1, 2026. Also see MAB current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Mabion S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Mabion S.A. (2015–2026)
Market capitalization of Mabion S.A. from 2015 to today. Between 2015 and today, Mabion S.A.'s market cap moved from $208.88 Million to $ 35.14 Million, with a yearly change of -15.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł35.14 Million | +13.18% |
| 2025 | zł31.05 Million | -21.57% |
| 2024 | zł39.59 Million | -50.96% |
| 2023 | zł80.73 Million | -13.57% |
| 2022 | zł93.41 Million | -65.63% |
| 2021 | zł271.78 Million | +194.46% |
| 2020 | zł92.30 Million | -73.05% |
| 2019 | zł342.50 Million | -11.09% |
| 2018 | zł385.21 Million | -23.23% |
| 2017 | zł501.75 Million | +51.96% |
| 2016 | zł330.18 Million | +58.07% |
| 2015 | zł208.88 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 1st, 2026 the market cap of Mabion S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.14 Million USD |
| MoneyControl | $35.14 Million USD |
| MarketWatch | $35.14 Million USD |
| marketcap.company | $35.14 Million USD |
| Reuters | $35.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartere… Read more